- Email: [email protected]
4957869 Immunogenic peptide corresponding to P. vivax CS protein
xiv
New Patents
Novel compositions are disclosed for use in the treatment or diagnosis of bovine pasteurellosis, commonly referred to as Shipping Fever. Cellfree Pasteurella haemolytica supernatants are employed to provide individual antigen compositions, identified through reaction with sera from naturally-infected or convalescent cattle. In particular, at least seven individual P. hameolytica antigen groups were recognized in cell-free culture supernatants. Purified P. haemolytica supernatant, formulated in a suitable pharmaceutical vaccine composition is shown to elicit a specific immune response, in both cows and rabbits, directed against the individual immunoreactive P. haemolytica polypeptides identified. Also disclosed are novel recombinant cells, plasmids and bacteriophage which include transcriptionally active P. haemolytica antigen genes. Recombinant clones are similarly selected to be reactive with naturally-infected antisera. Examples, and further disclosure, are also provided which demonstrate the utility of a presently disclosed antibody and antigen compositions in immunodetection of both antigens and antibodies in various biological samples.
4957863 METHOD OF INCREASING YIELD OF T-PA IN CELL CULTURE Michael A Sanzo, Medora M Hardy, Joseph Feder assigned to Monsanto Company A method is disclosed for increasing the yield of t-PA in culture of mammalian cells comprising introducing antibodies to the t-PA of said cells into the cell culture nutrient medium, allowing the ceils to grow, and then recovering t-PA from the t-PA-antibody complex thus found in the conditioned medium by exchanging antibody in the complex for t-PA antibody immobilized on an inert support.
4957869 IMMUNOGENIC PEPTIDE CORRESPONDING TO P. VIVAX CS PROTEIN David E Arnot, Vincenzo Enea, Ruth Nussenzweig, Victor N Nussenzweig assigned to New York University Disclosed are peptides comprising the amino acids See Patent for Tabular Presentation PS
wherein X represents Asp or Aia, said peptides eleciting antibodies against the P. vivax circumsporozoite protein. Also disclosed are D N A sequences coding for such peptides.
4958009 ANTI-HUMAN OVARIAN CANCER IMMUNOTOXINS AND METHODS OF USE THEREOF Michael J Bjorn, David FitzGerald, Arthur E Frankel, Walter Laird, Ira H Pastan, David B Ring, Mark Willingham, Jeffrey L Windelhake assigned to Cetus Corporation lmmunotoxins comprising a cytotoxic moiety and monoclonal antibodies which bind to human ovarian cancer tissue having at least one of the following capabilities are claimed: cytotoxic ID50 of 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens to which the monoclonal antibody of the immunotoxin bind are identified and characterize the immunotoxins. Methods of killing human ovarian cancer cells, retarding the growth of human ovarian cancer tumors in mammals or extending the survival of mammals carrying human ovarian cancer tumors are claimed.
4959182 METHOD AND COMPOSITIONS PROVIDING ENHANCED CHEMILUMINESCENCE FROM 2-DIOXETANES
1,
Arthur P Schaap assigned to Board of Governors of Wayne State University A method and compositions including a 1,2dioxetane and a fluorescent compound is described. In particular, enzymatic triggering of a triggerable 1,2-dioxetane admixed with a surfactant and the fluorescent compound attached to a hydrocarbon to provide a co-surfactant in a micelle or other structure providing close association of these molecules is described. The method and compositions are useful in immunoassays and in DNA probes used for various purposes.
New Patents
Novel compositions are disclosed for use in the treatment or diagnosis of bovine pasteurellosis, commonly referred to as Shipping Fever. Cellfree Pasteurella haemolytica supernatants are employed to provide individual antigen compositions, identified through reaction with sera from naturally-infected or convalescent cattle. In particular, at least seven individual P. hameolytica antigen groups were recognized in cell-free culture supernatants. Purified P. haemolytica supernatant, formulated in a suitable pharmaceutical vaccine composition is shown to elicit a specific immune response, in both cows and rabbits, directed against the individual immunoreactive P. haemolytica polypeptides identified. Also disclosed are novel recombinant cells, plasmids and bacteriophage which include transcriptionally active P. haemolytica antigen genes. Recombinant clones are similarly selected to be reactive with naturally-infected antisera. Examples, and further disclosure, are also provided which demonstrate the utility of a presently disclosed antibody and antigen compositions in immunodetection of both antigens and antibodies in various biological samples.
4957863 METHOD OF INCREASING YIELD OF T-PA IN CELL CULTURE Michael A Sanzo, Medora M Hardy, Joseph Feder assigned to Monsanto Company A method is disclosed for increasing the yield of t-PA in culture of mammalian cells comprising introducing antibodies to the t-PA of said cells into the cell culture nutrient medium, allowing the ceils to grow, and then recovering t-PA from the t-PA-antibody complex thus found in the conditioned medium by exchanging antibody in the complex for t-PA antibody immobilized on an inert support.
4957869 IMMUNOGENIC PEPTIDE CORRESPONDING TO P. VIVAX CS PROTEIN David E Arnot, Vincenzo Enea, Ruth Nussenzweig, Victor N Nussenzweig assigned to New York University Disclosed are peptides comprising the amino acids See Patent for Tabular Presentation PS
wherein X represents Asp or Aia, said peptides eleciting antibodies against the P. vivax circumsporozoite protein. Also disclosed are D N A sequences coding for such peptides.
4958009 ANTI-HUMAN OVARIAN CANCER IMMUNOTOXINS AND METHODS OF USE THEREOF Michael J Bjorn, David FitzGerald, Arthur E Frankel, Walter Laird, Ira H Pastan, David B Ring, Mark Willingham, Jeffrey L Windelhake assigned to Cetus Corporation lmmunotoxins comprising a cytotoxic moiety and monoclonal antibodies which bind to human ovarian cancer tissue having at least one of the following capabilities are claimed: cytotoxic ID50 of 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens to which the monoclonal antibody of the immunotoxin bind are identified and characterize the immunotoxins. Methods of killing human ovarian cancer cells, retarding the growth of human ovarian cancer tumors in mammals or extending the survival of mammals carrying human ovarian cancer tumors are claimed.
4959182 METHOD AND COMPOSITIONS PROVIDING ENHANCED CHEMILUMINESCENCE FROM 2-DIOXETANES
1,
Arthur P Schaap assigned to Board of Governors of Wayne State University A method and compositions including a 1,2dioxetane and a fluorescent compound is described. In particular, enzymatic triggering of a triggerable 1,2-dioxetane admixed with a surfactant and the fluorescent compound attached to a hydrocarbon to provide a co-surfactant in a micelle or other structure providing close association of these molecules is described. The method and compositions are useful in immunoassays and in DNA probes used for various purposes.